Cencora is moving forward with the acquisition of the majority of outstanding equity interests it does not already own in OneOncology, a national platform supporting independent oncology practices, from TPG and other shareholders. The agreement values OneOncology at $7.4 billion, with Cencora set to pay approximately $3.6 billion to acquire these interests and retire $1.3 billion in corporate debt, for a total cash consideration of around $5.0 billion. OneOncology's affiliated practices and management will retain a minority stake in the company. The transaction is expected to close by the end of Cencora's fiscal 2026 second quarter. Cencora plans to fund the deal through new debt financing and has paused share repurchases in anticipation of the acquisition. The company also reiterated its fiscal 2026 guidance, indicating that full-year adjusted diluted EPS is likely to be toward the lower end of its previously stated range.